Trial
NCT01940796
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Massachusetts General Hospital
Collaborators
Seagen Inc.
Condition
Graft-vs-Host Disease
Intervention
Brentuximab Vedotin
Why stopped
Toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-26